ACR 2021

axPsA is axSpA is not...!?

IL-17 pathway important for pain in PsA

ARIAA: prevention study or very early treatment of RA?

No need for methotrexate in ustekinumab treatment in…

New treatment alternative in GCA: promising secukinumab…

Pulmonary involvement and possible therapy concepts in…

Tofacitinib is associated with a slightly increased…

Statins reduce cardiovascular risk and​ mortality -…

Nausea & alopecia with MTX in RA

Cycling JAKi compared to switching to biologic DMARD in…

We need predictors of response for RA treatment

Abatacept may reduce subclinical inflammation in RA-at…

Discordance between patients and physicians in RA

Long awaited - MACE data from ORAL surveillance

Cardiovascular disease in RA

Skifte mellom JAK hemmere sammenliknet med skifte til…

Quels marqueurs de réponse aux traitements dans la…

Las estatinas reducen el riesgo cardiovascular y la…

Quels effets indésirables peuvent être associés à la…

Lange erwartet - MACE-Daten zur ORAL Surveillance

Abatacept reduce la inflamación subclínica en pacientes…

Tofacitinid se asocia con un ligero incremento del…

Axial PsA MRI data

No need for MTX in ustekinumab-treated patients

Anemia is an issue in PsA - proper treatment possible!

Association of C-reactive protein and non-steroidal…

Joint effusions and enthesitis after physical exertion

Guselkumab in axial symptoms

Secukinumab vs TNF-α blockers in enthesitis

Upadacitinib in PsA

Pain differs: Superior effect of IL-17-inhibition vs.…

Prediction of psoriatic arthritis in patients with…

Tildrakizumab in PsA

Osteoporosis in PsA

Guselkumab: the better ustekinumab?!

PET/CT in diagnosis for PsA

Anämie bei PsA ist ein Thema - effektive Therapie…

Gelenkergüsse und Enthesitis nach körperlicher…

Studio di confronto tra i vari indici compositi per la…

Guselkumab: das bessere Ustekinumab?!

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Associazione di livelli di PCR e uso di FANS con gli…

Upadacitinib bei PsA

Secukinumab vs TNF-α Blocker bei Enthesitis

Previsione di sviluppo di artrite psoriasica in…

Osteoporose bei PsA

Datos de RM en APs axial

Tildrakizumab bei PsA

PET-CT zur Quantifizierung der Entzündung

Guselkumab bei axialer Symptomatik

Axial PsA MRI data

Dose tapering of TNF inhibitors in axSpA

Self-monitoring of disease activity with a smartphone…

l’auto-monitoraggio di malattia è fattibile nella…

Datos de RM en APs axial

Inhibidores JAK: nuevas dianas en EspAax

Not yet a new standard: belimumab + rituximab

JAK-Inhibitor Baricitinib in Phase II erfolgreich

A new therapeutic approach for giant cell arteritis?

PET as a predictor of vascular damage in large-vessel…

Secukinumab in giant cell arteritis

Secukinumab nell'arterite a cellule giganti

Baricitinib nell'arterite a cellule giganti recidivante

Neuer Therapieansatz für die Riesenzellarteriitis?

Breakthrough infections after SARS-CoV2-vaccination -…

Analysis of COVID-19 infection among vaccinated…

Vaccination against Delta variant worse in patients…

Breakthrough infections after SARS-CoV2-vaccination -…

Anticytokine antibodies causing severe microbacterial…

Booster with which one if there is no seroconversion?

Immune responses to COVID-19 vaccines

Impact of COVID-19 on patients with rheumatic diseases

Should we use ultra-low-dose rituximab during the…

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Immunresponser til COVID-19 vaksiner

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

Womit boostern bei fehlender Serokonversion?

TNF-Blocker reduzieren Antikörperantwort bei…

Pearls and myths in rheumatology

CBD - an alternative therapy for chronic pain

Skin findings in patients of color with rheumatic…

Therapeutic drug monitoring - a randomized controlled…

PROs from a real-world study on etanercept biosimilar -…

Neue spannende Daten - Nahrungsergänzung mit Vitamin D…